🇺🇸 FDA

Company profile · Sponsor

Vanda

Vanda Pharmaceuticals Netherlands B.V.

VNDA · NYSE pharma WASHINGTON, DC, EU
Pipeline
24
Drugs
5
Patents
8

Quick answer

Vanda (VNDA) is a pharma company. headquartered in WASHINGTON, DC, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 5 drugs, and 8 patents to this profile..

Company facts

Ticker VNDA
Exchange NYSE
Company type pharma
Headquarters WASHINGTON, DC, EU
SEC CIK 0001347178

Pipeline (24)

Search pipeline →

  1. 20 mg VEC-162

    Vanda

    Insomnia

    phase 3 small molecule completed

    1 trial

  2. 750 mg Imsidolimab

    Vanda

    Generalized Pustular Psoriasis

    phase 3 small molecule completed

    1 trial

  3. Double-blind 200 mg imsidolimab

    Vanda

    Generalized Pustular Psoriasis

    phase 3 small molecule terminated

    1 trial

  4. Iloperidone

    Vanda

    Bipolar I Disorder

    phase 3 small molecule completed

    2 trials

  5. Milsaperidone

    Vanda

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  6. Placebo will be provided in size and appearance identical to those containing milsaperidone and will be administered orally., Milsaperidone, Milsaperidone, Milsaperidone

    Vanda

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  7. Ponesimod

    Vanda

    Moderate-to-severe Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  8. Tasimelteon

    Vanda

    Jet Lag Type Insomnia

    phase 3 small molecule completed

    1 trial

  9. Tasimelteon

    Vanda

    Sleep Wake Disorders

    phase 3 small molecule active

    2 trials

  10. Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

    Vanda

    Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  11. Tasimelteon Oral Suspension

    Vanda

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  12. Tradipitant

    Vanda

    Nausea and Vomiting

    phase 3 small molecule active

    1 trial

  13. Tradipitant

    Vanda

    Motion Sickness

    phase 3 small molecule active

    4 trials

  14. Tradipitant

    Vanda

    Idiopathic Gastroparesis

    phase 3 small molecule active

    2 trials

  15. Tradipitant

    Vanda

    Atopic Dermatitis

    phase 3 small molecule completed

    3 trials

  16. Tradipitant

    Vanda

    Coronavirus Infection

    phase 3 small molecule active

    1 trial

  17. VEC-162 20 mg

    Vanda

    Primary Insomnia

    phase 3 small molecule completed

    1 trial

  18. VQW-765

    Vanda

    Social Anxiety Disorder (SAD)

    phase 3 small molecule active

    1 trial

  19. tasimelteon

    Vanda

    Non 24 Hour Sleep Wake Disorder

    phase 3 small molecule active

    4 trials

  20. tasimelteon

    Vanda

    Smith-Magenis Syndrome

    phase 3 small molecule completed

    1 trial

  21. tasimelteon

    Vanda

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  22. Iloperidone

    Vanda

    Parkinson Disease Psychosis

    phase 2 small molecule terminated

    1 trial

  23. Iloperidone crystalline formulation

    Vanda

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  24. Imsidolimab

    Vanda

    Hidradenitis Suppurativa

    phase 2 mab completed

    1 trial

Drugs (5)

Search drugs →

  1. iloperidone

    FANAPTUM

    ORAL approved

    N05AX14

  2. milsaperidone

    BYSANTI

    ORAL approved

  3. ponesimod

    PONVORY

    ORAL approved

    L04AE04

  4. tasimelteon

    HETLIOZ

    ORAL approved

    N05CH

  5. tradipitant

    NEREUS

    ORAL approved

Patents (8)

Search patents →

  1. US 12427132

    Method of improving sleep

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12419869

    Methods of treating multiple sclerosis

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12409167

    Pharmaceutical combination comprising a selective S1P1 receptor agonist

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12403134

    Method for improving or enhancing cognition

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12357616

    Methods of treating multiple sclerosis

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12336980

    Dosing regimen for a selective S1P1 receptor agonist

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12318375

    Method of treatment with tradipitant

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12201604

    Treatment of circadian rhythm disorders

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Vanda?

Vanda (VNDA) is a pharma company. headquartered in WASHINGTON, DC, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 5 drugs, and 8 patents to this profile..

What pipeline programs does Vanda sponsor?

We track 24 ClinicalTrials.gov-linked programs for Vanda, including 20 mg VEC-162 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Vanda company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.